Novartis' Cosentyx keeps up the good clearance through Year 4: Study

Novartis HQ cropped

Novartis’ Cosentyx has a head start on the next-gen psoriasis pack, but the company is still gunning to build its lead before a raft of new competitors arrive. And now, the Swiss drugmaker has some long-term data in hand that could help it on that quest.

Over the weekend, the pharma giant unveiled results showing that its psoriasis star could deliver high--and long-lasting--skin clearance in moderate-to-severe psoriasis patients over four years of therapy. 68.5% of patients in the study achieved clear or almost clear skin at the Year 1 mark, and that rate holds steady, holding at 66.4% at Year 4.

And those whose skin cleared completely on Cosentyx--43.8% of patients--got to keep enjoying that status, too, with the rate staying put at 43.5% at Year 4.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Since Novartis won approval for Cosentyx in January 2015, the company hasn’t slowed down with the med. The newcomer racked up $261 million in 2015 after launching in February, and early this year, it snagged a pair of new indications--psoriatic arthritis and ankylosing spondylitis--that’ll help pad that total for this year.

Still, though, Cosentyx will be far from alone in any of those disease areas. In psoriasis, Eli Lilly launched new-age rival Taltz earlier this year, and others aren’t far behind. Valeant is currently waiting for an FDA decision after an advisory panel backed its candidate brodalumab, and Johnson & Johnson over the weekend rolled out data showing its prospect guselkumab had beaten out AbbVie inflammatory giant Humira in a head-to-head study.

And in psoriatic arthritis, Pfizer’s Xeljanz for one is gearing up to provide a challenge. Companies including J&J--which makes blockbuster Stelara--could give Novartis a run for its money in ankylosing spondylitis, too, research and consulting firm GlobalData predicted last year. 

- read Novartis' release

Related Articles:
J&J's next-gen psoriasis med tops Humira in head-to-head showdown
Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals
Analyst: J&J's Stelara to challenge Novartis in ankylosing spondylitis
Pfizer gives up on a pair of Xeljanz indications--and it may dump psoriasis, too
 

Read more on

Suggested Articles

FDA officials say Novartis took too long to launch a formal probe into allegations of Zolgensma data manipulation.

Should Johnson & Johnson owe billions to fix Oklahoma's opioid crisis? After weeks of trial testimony, a judge will have his say Monday afternoon.

After Endo and Allergan agreed to settle with two Ohio counties on opioid charges this week, the state’s AG has a message: You’re not off the hook.